

Rhythm recruits first patient in ColoSTAT® clinical trial

- **Study 7 first patient recruited on schedule**
- **Trial set to be completed by Q4 2019**

18 March 2019, Melbourne: Adelaide's Lyell McEwin Hospital is the first study site to recruit a patient for Rhythm Biosciences Limited (ASX:RHY) 1,000-patient prospective clinical trial (Study 7) of its blood test, ColoSTAT®, for the early detection of colorectal cancer.

"We are excited to have our first patient enrolled in this important study. ColoSTAT® has the potential to save many lives through early screening," said Professor Rajvinder Singh, the principal investigator for this site.

"I have recently visited Lyell McEwin Hospital where I saw that there is a well-qualified and enthusiastic team behind this trial. We look forward to further recruitment here and the addition of further trial centres coming on line," said Rhythm Biosciences CEO Glenn Gilbert. "At our recent AGM, I indicated we would recruit the first patient into Study 7 in Q1 2019, so I am pleased to see this milestone has been met" Mr Gilbert added.

The trial involves a prospective, cross-sectional, multi-centre study to evaluate the diagnostic performance of ColoSTAT® for detecting colorectal cancers and advanced adenomas relative to colonoscopy, as well as related comparisons to the currently used Faecal Immunochemical Test.

Colorectal cancer is the second most frequent cause of cancer-related deaths in the industrial world. It is curable in 90% of cases if detected early, but participation in screening is low. ColoSTAT® has the potential to make screening simple and increase participation.

Rhythm Biosciences also expects in the coming months to sign up further hospitals to the ColoSTAT® trial. Study 7 is expected to be completed by Q4 2019.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

Shane Tanner
Chairman
+61 411 107 099

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

Rhythm Biosciences

ACN: 619 459 335
ASX: RHY

Issued Capital

100,750,000 Shares
3,504,200 Options and
Performance Shares

Australian Registered Office

Level 17, 500 Collins Street
Melbourne VIC 3000
www.rhythmbio.com

Directors

Shane Francis Tanner – Chairman of the Board
Trevor John Lockett – Executive Director
Louis James Panaccio – Non-Executive Director
David John White – Non-Executive Director

About Rhythm Biosciences

ASX-listed Rhythm Biosciences is developing and commercialising a screening and diagnostic tool for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to or are unable to be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.